Back to Search Start Over

Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle.

Authors :
López-Canul, Martha
Min, Seung Hyun
Posa, Luca
De Gregorio, Danilo
Bedini, Annalida
Spadoni, Gilberto
Gobbi, Gabriella
Comai, Stefano
Source :
International Journal of Molecular Sciences; May2019, Vol. 20 Issue 10, p2452, 1p, 1 Diagram, 5 Graphs
Publication Year :
2019

Abstract

Melatonin (MLT) is a neurohormone that regulates many physiological functions including sleep, pain, thermoregulation, and circadian rhythms. MLT acts mainly through two G-protein-coupled receptors named MT<subscript>1</subscript> and MT<subscript>2</subscript>, but also through an MLT type-3 receptor (MT<subscript>3</subscript>). However, the role of MLT receptor subtypes in thermoregulation is still unknown. We have thus investigated the effects of selective and non-selective MLT receptor agonists/antagonists on body temperature (T<subscript>b</subscript>) in rats across the 12/12-h light–dark cycle. Rectal temperature was measured every 15 min from 4:00 a.m. to 9:30 a.m. and from 4:00 p.m. to 9:30 p.m., following subcutaneous injection of each compound at either 5:00 a.m. or 5:00 p.m. MLT (40 mg/kg) had no effect when injected at 5 a.m., whereas it decreased T<subscript>b</subscript> during the light phase only when injected at 5:00 p.m. This effect was blocked by the selective MT<subscript>2</subscript> receptor antagonist 4P-PDOT and the non-selective MT<subscript>1</subscript>/MT<subscript>2</subscript> receptor antagonist, luzindole, but not by the α<subscript>1</subscript>/MT<subscript>3</subscript> receptors antagonist prazosin. However, unlike MLT, neither the selective MT<subscript>1</subscript> receptor partial agonist UCM871 (14 mg/kg) nor the selective MT<subscript>2</subscript> partial agonist UCM924 (40 mg/kg) altered T<subscript>b</subscript> during the light phase. In contrast, UCM871 injected at 5:00 p.m. increased T<subscript>b</subscript> at the beginning of the dark phase, whereas UCM924 injected at 5:00 a.m. decreased T<subscript>b</subscript> at the end of the dark phase. These effects were blocked by luzindole and 4P-PDOT, respectively. The MT<subscript>3</subscript> receptor agonist GR135531 (10 mg/kg) did not affect T<subscript>b</subscript>. These data suggest that the simultaneous activation of both MT<subscript>1</subscript> and MT<subscript>2</subscript> receptors is necessary to regulate T<subscript>b</subscript> during the light phase, whereas in a complex but yet unknown manner, they regulate T<subscript>b</subscript> differently during the dark phase. Overall, MT<subscript>1</subscript> and MT<subscript>2</subscript> receptors display complementary but also distinct roles in modulating circadian fluctuations of T<subscript>b</subscript>. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16616596
Volume :
20
Issue :
10
Database :
Complementary Index
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
136750636
Full Text :
https://doi.org/10.3390/ijms20102452